General Information of Drug (ID: DMGSEB0)

Drug Name
CKD-516 Drug Info
Synonyms S-516; Tubulin polymerization inhibitor (iv, solid cancer), Chong Kun Dang
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
46929961
CAS Number
CAS 1240321-53-2
TTD Drug ID
DMGSEB0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Tubulin beta (TUBB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vincristine DMINOX3 Acute lymphoblastic leukaemia 2A85 Approved [3]
Albendazole DMYZ57N Echinococcus granulosus infectious disease Approved [4]
Vindesine DMVR628 Acute lymphoblastic leukaemia 2A85 Approved [5]
Taxol DMUOT9V Breast cancer 2C60-2C65 Approved [6]
Mebendazole DMO14SG Ascariasis 1F62 Approved [4]
Plinabulin DMD7L48 Non-small-cell lung cancer 2C25.Y Phase 3 [7]
Batabulin DMHWE5R Solid tumour/cancer 2A00-2F9Z Phase 2/3 [8]
ABT-751 DMNG35S Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
DOLASTATIN-10 DMDUV1S Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
BNC-105 DMJC8DR Mesothelioma 2C51.2 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01560325) Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers. U.S. National Institutes of Health.
2 CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
5 Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
6 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
7 NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
8 Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
9 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
10 Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
11 The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.